International
New timeline for 2026 aims to provide clearer guidance to firms and practitioners on the full jurisdictional market view
An Australian top court decision clarifying honest concurrent use and wins by publishers against AI platforms were also among the top talking points
AIPPI has pulled the plug on its planned 2027 World Congress, and INTA has delayed hosting a meeting there, but the concerns won’t abate
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Sponsored
Sponsored
-
Sponsored by Bird & BirdMax Walters joins Sally Shorthose and James Baillieu of Bird & Bird and Henry Hadad of Bristol Myers Squibb to discuss how COVID-19 has shaped transactional work -
Sponsored by Bird & BirdCharlotte Kilpatrick joins Steve Mortinger of IBM and Toby Bond and Katharine Stephens of Bird & Bird to discuss how data rights are reshaping IP
-
Sponsored by Bird & BirdRichard Vary, Clemens Heusch and Matthias Schneider reveal their views on component-level versus end-point licensing and Unwired Planet
